Thursday, May 30, 2024 10:01:56 AM
I had the right idea but the wrong seller. Not 100% sure (pretty sure though) but I think OTLK weakness is due to the 13G filer below. His cost basis is much higher and was not included in the recent transaction. He doesn’t possess any material private information, so the weakness should be temporary and not impact our longer-term economics.
13G filing
If true, we should see 13/G amendment 45 days following the 2Q quarter end.
Filing Date: 2023-02-21
SOLE VOTING POWER: 20,000,000 => 1,000,000 split adjusted
The SEC Adopts New Timing Requirements for Beneficial Ownership Reporting
Amendments to any Schedule 13G filing must be made within 45 days after the end of the calendar quarter in which any reportable change occurs. In addition, Qualified Institutional Investors must file an amendment within five business days (previously 10 days) after month-end in which such Qualified Institutional Investor’s beneficial ownership first exceeds 10% of a covered class or any 5% increase or decrease in beneficial ownership of a covered class. Passive Investors must file an amendment within two business days (previously “promptly”) after such Passive Investor’s beneficial ownership first exceeds 10% of a covered class or any 5% increase or decrease in beneficial ownership of a covered class. The SEC further provided that the triggering event for filing amendments under Schedule 13G is a “material” change in the information previously provided vs. “any” change in the information previously provided.
13G filing
If true, we should see 13/G amendment 45 days following the 2Q quarter end.
Filing Date: 2023-02-21
SOLE VOTING POWER: 20,000,000 => 1,000,000 split adjusted
The SEC Adopts New Timing Requirements for Beneficial Ownership Reporting
Amendments to any Schedule 13G filing must be made within 45 days after the end of the calendar quarter in which any reportable change occurs. In addition, Qualified Institutional Investors must file an amendment within five business days (previously 10 days) after month-end in which such Qualified Institutional Investor’s beneficial ownership first exceeds 10% of a covered class or any 5% increase or decrease in beneficial ownership of a covered class. Passive Investors must file an amendment within two business days (previously “promptly”) after such Passive Investor’s beneficial ownership first exceeds 10% of a covered class or any 5% increase or decrease in beneficial ownership of a covered class. The SEC further provided that the triggering event for filing amendments under Schedule 13G is a “material” change in the information previously provided vs. “any” change in the information previously provided.
Recent OTLK News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/01/2026 01:15:32 PM
- Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg) • GlobeNewswire Inc. • 06/01/2026 12:46:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2026 08:30:49 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/29/2026 12:30:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/28/2026 09:09:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/27/2026 07:29:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/27/2026 07:24:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/26/2026 11:15:41 AM
- Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg) • GlobeNewswire Inc. • 05/26/2026 11:00:00 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2026 09:03:14 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2026 08:31:12 PM
- Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/15/2026 08:05:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/13/2026 09:12:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2026 08:36:26 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 05/07/2026 08:24:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/23/2026 08:30:39 PM
- Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering • GlobeNewswire Inc. • 04/23/2026 08:05:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 04/23/2026 11:30:17 AM
- Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/21/2026 08:15:44 PM
- Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg) • GlobeNewswire Inc. • 04/21/2026 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 08:15:24 PM
- Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA • GlobeNewswire Inc. • 04/07/2026 12:50:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 09:04:56 PM
- Outlook Therapeutics Announces Closing of $5.0 Million Public Offering • GlobeNewswire Inc. • 03/25/2026 08:05:00 PM
